Hi, what are you looking for?
New OphthaliX strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases.
Interim results from this Phase II/III trial and final results from the prior Phase II trial in psoriasis were both positive
"The completion of the development of our commercial A3AR biomarker test kit comes at a very important time since we plan to use the...
Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, reported it has received positive...
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the Design of...
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, treated the first patient with...
Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a...
– Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging. – CEO Pnina Fishman / Ilan Besor...
– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin...